Pfizer Inc. (PFE)
Pfizer: Value Play or Past Its Prime?
Explore the exciting world of Pfizer (PFE -0.61%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Did Pfizer Delay Covid Vaccine Announcement Until After 2020 Election? Here's What We Know.
Federal investigators are investigating claims suggesting Pfizer delayed announcing test results of its Covid vaccine until after the 2020 presidential election, the Wall Street Journal reported, bolstering a claim by President Donald Trump, who has claimed for years the company withheld vaccine results to impact his chances at reelection.
Why Pfizer Is My Largest Healthcare Position
Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment toward the healthcare sector, but in some instances, this dour take isn't entirely warranted.
Feds probe tip that Pfizer delayed announcing COVID vaccine's success until after 2020 election: report
The report said GSK's former head of vaccine development, Philip Dormitzer, who joined the company after working at rival Pfizer, had told his GSK colleagues about the delay.
Here's Why Pfizer (PFE) Fell More Than Broader Market
In the latest trading session, Pfizer (PFE) closed at $25.21, marking a -1.33% move from the previous day.
US prosecutors probe tip about timing of Pfizer's COVID vaccine, WSJ reports
Federal prosecutors in Manhattan are probing a claim brought by GSK that Pfizer delayed announcing the success of its COVID-19 vaccine in 2020 until after that year's election, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.
Pfizer Is Trading As If It's 2009 Again
Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue decline. Recent acquisitions and product launches in oncology and vaccines strengthen Pfizer's market position and future revenue streams. Despite potential risks like tariffs and drug development delays, Pfizer's current valuation is attractive, resembling 2008-2009 levels.
Pfizer Is a Dirt-Cheap High-Yield Stock, But Is It a Buy?
Of late, pharmaceutical behemoth Pfizer Inc.'s PFE stock has struggled, but it remains a bargain with generous dividends. Its financials aren't in bad shape either.
Pfizer: Bulls Need To Check Out Its Graham P/E
Bulls have good reasons to love PFE, with attractive dividend yield and low P/E ratio being two of the frequently mentioned ones. But I urge potential investors to consider the contradicting factors against the bullish sentiments. With its bleak growth outlook, the Graham P/E ratio suggests a valuation premium instead of a discount.
Pfizer Sells Remaining 7.3% Stake in Haleon for Around 3.3B
Pfizer divests its 7.3% remaining stake in Haleon to institutional investors and Haleon itself.
3 Reasons Pfizer Stock Could Be a Steal of a Deal in 2025
If you're looking for reasonably priced stocks to pick up right now, you shouldn't overlook Pfizer (PFE -0.50%). The pharmaceutical giant isn't as risky an investment as it may appear to be.
2 High-Yield Dividend Stocks That Are Bargain Buys Right Now
Healthcare is a defensive sector that is more resilient to economic downturns than most others. That's one of several reasons it is home to solid dividend stocks, including Pfizer (PFE -0.49%) and Bristol Myers Squibb (BMY 0.23%), two of the leading pharmaceutical companies in the world.
